Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine

被引：0
|
作者：
Day, Kathleen A. [1 ]
Ament, Michael [2 ]
Stauffer, Virginia L. [1 ]
Skljarevski, Vladimir [1 ]
Zhang, Qi [1 ]
Pearlman, Eric M. [1 ]
Aurora, Sheena K. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Ament Headache Ctr, Denver, CO 80206 USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2018年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
O31
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
    Ament, Michael
    Day, Kathleen
    Stauffer, Virginia L.
    Skljarevski, Vladimir
    Rettiganti, Mallikarjuna
    Pearlman, Eric
    Aurora, Sheena K.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (01):
  • [2] Correction to: Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
    Michael Ament
    Kathleen Day
    Virginia L. Stauffer
    Vladimir Skljarevski
    Mallikarjuna Rettiganti
    Eric Pearlman
    Sheena K. Aurora
    The Journal of Headache and Pain, 2021, 22
  • [3] Effect of Galcanezumab on Severity of Headache and Associated Symptoms of Migraine in Phase 3 Trials in Patients with Episodic or Chronic Migraine
    Day, Kathleen A.
    Ament, Michael
    Stauffer, Virginia L.
    Skljarevski, Vladimir
    Rettiganti, Mallikarjuna
    Pearlman, Eric M.
    Aurora, Sheena K.
    NEUROLOGY, 2019, 92 (15)
  • [4] Immunogenicity findings from Phase 3 galcanezumab trials in patients with episodic or chronic migraine
    Martinez, James M.
    Garce, Sandra
    Anglin, Greg
    Hodsdon, Michael
    Kielbasa, William
    Moser, Brian A.
    Pearlman, Eric
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [5] Immunogenicity Assessment from Phase 3 Galcanezumab Trials in Patients with Episodic or Chronic Migraine
    Martinez, James M.
    Hindiyeh, Nada
    Anglin, Greg
    Kalidas, Kavita
    Hodsdon, Michael E.
    Kielbasa, William
    Moser, Brian A.
    Pearlman, Eric
    Garces, Sandra
    NEUROLOGY, 2019, 92 (15)
  • [6] Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine
    Martinez, James M.
    Hindiyeh, Nada
    Anglin, Greg
    Kalidas, Kavita
    Hodsdon, Michael E.
    Kielbasa, William
    Moser, Brian A.
    Pearlman, Eric M.
    Garces, Sandra
    CEPHALALGIA, 2020, 40 (09) : 978 - 989
  • [7] Galcanezumab Effects on Migraine Severity and Symptoms in Japanese Patients with Episodic Migraine: Secondary Analysis of a Phase 2 Randomized Trial
    Igarashi, Hisaka
    Shibata, Mamoru
    Ozeki, Akichika
    Matsumura, Taka
    NEUROLOGY AND THERAPY, 2023, 12 (01) : 73 - 87
  • [8] Galcanezumab Effects on Migraine Severity and Symptoms in Japanese Patients with Episodic Migraine: Secondary Analysis of a Phase 2 Randomized Trial
    Hisaka Igarashi
    Mamoru Shibata
    Akichika Ozeki
    Taka Matsumura
    Neurology and Therapy, 2023, 12 : 73 - 87
  • [9] Shift from Chronic Migraine to Episodic Migraine Status in a Long-Term Phase 3 Study of Galcanezumab
    Hindiyeh, N. A.
    Detke, H. C.
    Day, K.
    Lipsius, S.
    Aurora, S. K.
    Diener, H.
    HEADACHE, 2019, 59 : 103 - 103
  • [10] Shift from chronic migraine to episodic migraine status in a long-term phase 3 study of galcanezumab
    Detke, H.
    Day, K.
    Lipsius, S.
    Aurora, S. K.
    Hindiyeh, N.
    Diener, H-C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 425 - 425
12345